Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
- 2.7k Downloads
Purpose of Review
Obesity is a global health crisis with detrimental effects on all organ systems leading to worsening disease state and rising costs of care. Persons with obesity failing lifestyle therapies need to be escalated to appropriate pharmacological treatment modalities, medical devices, and/or bariatric surgery if criteria are met and more aggressive intervention is needed. The progression of severe obesity in the patient population coupled with related co-morbidities necessitates the development of novel therapies for the treatment of obesity. This development is preceded by increased understanding of the underpinnings of energy regulation and neurohormonal pathways involved in energy homeostasis.
Though there are approved anti-obesity drugs available in the USA, newer drugs are now in the pipeline for development given the urgent need. This review focuses on anti-obesity drugs in the pipeline including centrally acting agents (setmelanotide, neuropeptide Y antagonist [velneperit], zonisamide-bupropion [Empatic], cannabinoid type-1 receptor blockers), gut hormones and incretin targets (new glucagon-like-peptide-1 [GLP-1] analogues [semaglutide and oral equivalents], amylin mimetics [davalintide, dual amylin and calcitonin receptor agonists], dual action GLP-1/glucagon receptor agonists [oxyntomodulin], triple agonists [tri-agonist 1706], peptide YY, leptin analogues [combination pramlintide-metreleptin]), and other novel targets (methionine aminopeptidase 2 inhibitor [beloranib], lipase inhibitor [cetilistat], triple monoamine reuptake inhibitor [tesofensine], fibroblast growth factor 21), including anti-obesity vaccines (ghrelin, somatostatin, adenovirus36).
With these new drugs in development, anti-obesity therapeutics have potential to vastly expand allowing better treatment options and personalized approach to obesity care.
KeywordsAnti-obesity drugs Weight loss medications Novel targets Phase 1 and phase 2 trials Obesity pharmacotherapy Weight management
The authors thank A. McCarthy for editorial and administrative assistance.
No funding was provided for the drafting of this manuscript.
Compliance with Ethical Standards
Conflict of Interest
Gitanjali Srivastava has received compensation from Rhythm Pharmaceuticals for service on an advisory board.
Caroline Apovian has received research funding through grants from Orexigen, Aspire Bariatrics, GI Dynamics, MYOS, Takeda, Gelesis, Vela Foundation, Dr. Robert C. and Veronica Atkins Foundation, Coherence Lab, Energesis, Patient-Centered Outcomes Research Institute (PCORI), and the National Institutes of Health (NIH); has received compensation from Nutrisystem, Zafgen, Sanofi-Aventis, Orexigen, Novo Nordisk, GI Dynamics, Takeda, Scientific Intake, Gelesis, Merck, and Johnson & Johnson for service on advisory boards; and owns stock in Science-Smart LLC.
GS reports personal fees from Rhythm Pharmaceuticals, outside the submitted work. Dr. Apovian reports personal fees from Nutrisystem, personal fees from Zafgen, personal fees from Sanofi-Aventis, grants and personal fees from Orexigen, personal fees from NovoNordisk, grants from Aspire Bariatrics, grants and personal fees from GI Dynamics, grants from Myos, grants and personal fees from Takeda, personal fees from Scientific Intake, grants and personal fees from Gelesis, other from Science-Smart LLC, personal fees from Merck, personal fees from Johnson & Johnson, grants from Vela Foundation, grants from Dr. Robert C. and Veronica Atkins Foundation, grants from Coherence Lab, grants from Energesis, grants from PCORI, and grants from NIH, outside the submitted work. However, the authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.•• Apovian CM, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–62. https://doi.org/10.1210/jc.2014-3415. Provides current guidelines for clinical application of approved anti-obesity drugs. PubMedCrossRefGoogle Scholar
- 6.Weintraub M, Sundaresan PR, Schuster B, Ginsberg G, Madan M, Balder A, et al. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther. 1992;51:595–601.PubMedCrossRefGoogle Scholar
- 12.•• Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinology. 2017; https://doi.org/10.1038/nrendo.2017.122. Most recent review on current anti-obesity drugs in regard to efficacy, safety, and clinical application.
- 15.Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308. https://doi.org/10.3945/ajcn.111.024927.PubMedCrossRefGoogle Scholar
- 17.Chen KY, Muniyappa R, Abel BS, Mullins KP, Staker P, Brychta RJ, et al. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocrinol Metab. 2015;100:1639–45. https://doi.org/10.1210/jc.2014-4024.PubMedPubMedCentralCrossRefGoogle Scholar
- 19.Kievit P, Halem H, Marks DL, Dong JZ, Glavas MM, Sinnayah P, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes. 2013;62:490–7. https://doi.org/10.2337/db12-0598.PubMedPubMedCentralCrossRefGoogle Scholar
- 24.Release, O. P. I. P. Orexigen (R) Therapeutics phase 2b trial for Empatic(TM) meets primary efficacy endpoint demonstrating significantly greater weight loss versus comparators in obese patients. http://ir.orexigen.com/phoenix.zhtml%3Fc=207034%26p=irol-newsArticle%26ID=1336796%26highlight= Accessed September 13, 2017.
- 25.Guide to receptors and channels (GRAC), 4th Edition. Br J Pharmacol 2009;158 Suppl 1, S1–254, doi: https://doi.org/10.1111/j.1476-5381.2009.00499.x.
- 27.Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, Parker LA. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav. 2007;91:383–8. https://doi.org/10.1016/j.physbeh.2007.04.013.PubMedPubMedCentralCrossRefGoogle Scholar
- 29.Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology. 2003;167:103–11. https://doi.org/10.1007/s00213-002-1384-8.PubMedCrossRefGoogle Scholar
- 31.European Medicines Agency: European Public Assessment Report (EPAR) Acomplia. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000666/WC500021282.pdf Accessed September 27, 2017 (2007).
- 34.• Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19:1242–51. https://doi.org/10.1111/dom.12932. The aim of this trial was to investigate the mechanism of action of body weight loss with semaglutide, a new drug which has shown significant weight loss potential of almost 16% in clinical trials. PubMedPubMedCentralCrossRefGoogle Scholar
- 35.Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:355–66. https://doi.org/10.1016/S2213-8587(17)30085-2.PubMedCrossRefGoogle Scholar
- 36.Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, et al. Safety and efficacy of semaglutide once weekly versus sitagliptin once daily, both as monotherapy in Japanese subjects with type 2 diabetes. Diabetes Obes Metab. 2017;20:378–88. https://doi.org/10.1111/dom.13082.PubMedPubMedCentralCrossRefGoogle Scholar
- 37.Ahren B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5:341–54. https://doi.org/10.1016/S2213-8587(17)30092-X.PubMedCrossRefGoogle Scholar
- 40.Bailey RJ, Walker CS, Ferner AH, Loomes KM, Prijic G, Halim A, et al. Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes. Br J Pharmacol. 2012;166:151–67. https://doi.org/10.1111/j.1476-5381.2011.01717.x.PubMedPubMedCentralCrossRefGoogle Scholar
- 41.Mack CM, Soares CJ, Wilson JK, Athanacio JR, Turek VF, Trevaskis JL, et al. Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int J Obes. 2010;34:385–95. https://doi.org/10.1038/ijo.2009.238.CrossRefGoogle Scholar
- 43.Gydesen S, Andreassen KV, Hjuler ST, Christensen JM, Karsdal MA, Henriksen K. KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight. Am J Physiol Endocrinol Metab. 2016;310:E821–7. https://doi.org/10.1152/ajpendo.00514.2015.PubMedCrossRefGoogle Scholar
- 44.Hjuler ST, Andreassen KV, Gydesen S, Karsdal MA, Henriksen K. KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration. Eur J Pharmacol. 2015;762:229–38. https://doi.org/10.1016/j.ejphar.2015.05.051.PubMedCrossRefGoogle Scholar
- 45.Hjuler ST, Gydesen S, Andreassen KV, Karsdal MA, Henriksen K. The dual amylin- and calcitonin-receptor agonist KBP-042 works as adjunct to metformin on fasting hyperglycemia and HbA1c in a rat model of type 2 diabetes. J Pharmacol Exp Ther. 2017;362:24–30. https://doi.org/10.1124/jpet.117.241281.PubMedCrossRefGoogle Scholar
- 48.Parker JA, McCullough KA, Field BCT, Minnion JS, Martin NM, Ghatei MA, et al. Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int J Obes. 2013;37:1391–8. https://doi.org/10.1038/ijo.2012.227.CrossRefGoogle Scholar
- 52.R&D Pipeline. https://www.novonordisk.com/rnd/rd-pipeline.html Novo Nordisk Accessed August 28, 2017 (2017).
- 53.Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N. Ghrelin, CCK, GLP-1, and PYY(3-36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev. 2017;97:411–63. https://doi.org/10.1152/physrev.00031.2014.PubMedCrossRefGoogle Scholar
- 61.•• Tchang BG, Shukla AP, Aronne LJ. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives. Expert Opin Biol Ther. 2015;15:1061–75. https://doi.org/10.1517/14712598.2015.1052789. This paper covers the physiology of leptin, pharmacological properties of recombinant metreleptin, and its efficacy in the treatment of generalized lipodystrophy. PubMedCrossRefGoogle Scholar
- 63.Chan JL, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2011;17:922–32. https://doi.org/10.4158/ep11229.or.CrossRefGoogle Scholar
- 64.• Brown RJ, et al. Effects of metreleptin in pediatric patients with lipodystrophy. J Clin Endocrinol Metab. 2017;102:1511–9. https://doi.org/10.1210/jc.2016-3628. Metreleptin also has important implications in children with lipodsytrophy and low levels of leptin, leading to improved metabolic abnormalities. PubMedPubMedCentralCrossRefGoogle Scholar
- 65.Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol. 2016;9:59–68. https://doi.org/10.1586/17512433.2016.1096772.PubMedCrossRefGoogle Scholar
- 68.Myalept [package insert]. Amylin Pharmaceuticals https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s000lbl.pdf Acccessed September 5, 2017 (2014).
- 70.Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2011;13:169–80. https://doi.org/10.1111/j.1463-1326.2010.01337.x.PubMedCrossRefGoogle Scholar
- 79.The Boston Globe: Zafgen drug halted after second patient dies. https://www.bostonglobe.com/business/2015/12/03/fda-orders-zafgen-halt-clinical-trial-for-obesity-drug/PwGxnqvLoIYpXZN59hPT6M/story.html Accessed September 27, 2017 (2015).
- 83.Hansen HH, Jensen MM, Overgaard A, Weikop P, Mikkelsen JD. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacol Biochem Behav. 2013;110:265–71. https://doi.org/10.1016/j.pbb.2013.07.018.PubMedCrossRefGoogle Scholar
- 84.Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1906–13. https://doi.org/10.1016/S0140-6736(08)61525-1.PubMedCrossRefGoogle Scholar
- 85.Doggrell SS. Tesofensine—a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13. Expert Opin Investig Drugs. 2009;18:1043–6. https://doi.org/10.1517/13543780902967632.PubMedCrossRefGoogle Scholar
- 87.Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol. 2016;78:223–41. https://doi.org/10.1146/annurev-physiol-021115-105339.PubMedCrossRefGoogle Scholar
- 90.Cuevas-Ramos D & Aguilar-Salinas CA Modulation of energy balance by fibroblast growth factor 21. Horm Mol Biol Clin Inv 2016, 30, doi: https://doi.org/10.1515/hmbci-2016-0023.
- 99.• Na HN, Kim H, Nam JH. Prophylactic and therapeutic vaccines for obesity. Clin Exp Vaccine Res. 2014;3:37–41. https://doi.org/10.7774/cevr.2014.3.1.37. This review describes the ongoing development of therapeutic vaccines for the prevention of obesity, and the possibility of using inactivated adenovirus-36 as a vaccine and anti-obesity agent. PubMedCrossRefGoogle Scholar
- 104.Rossi M, Kim MS, Morgan DGA, Small CJ, Edwards CMB, Sunter D, et al. A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology. 1998;139:4428–31. https://doi.org/10.1210/endo.139.10.6332.PubMedCrossRefGoogle Scholar
- 106.Kumar KG, Sutton GM, Dong JZ, Roubert P, Plas P, Halem HA, et al. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice. Peptides. 2009;30:1892–900. https://doi.org/10.1016/j.peptides.2009.07.012.PubMedPubMedCentralCrossRefGoogle Scholar
- 107.• Anderson EJ, et al. 60 YEARS OF POMC: regulation of feeding and energy homeostasis by alpha-MSH. J Mol Endocrinol. 2016;56:T157–74. https://doi.org/10.1530/JME-16-0014. This review discusses the history of POMC mRNA and melanocortin peptides as well as the latest work attempting to unravel feeding and regulation in the CNS by alpha-MSH. PubMedPubMedCentralCrossRefGoogle Scholar
- 114.Rhythm Pharmaceuticals, Inc Product pipeline: peptide therapeutics for rare genetic deficiencies resulting in life-threatening metabolic disorders. http://www.rhythmtx.com/pipeline/product-pipeline/ Accessed August 28, 2017 (2017).
- 115.Double-blind, multi-center, randomized study to assess the efficacy and safety of velneperit (S-2367) and orlistat administered individually or combined with a reduced calorie diet (RCD) in obese subjects. https://clinicaltrials.gov/ct2/show/NCT01126970 Accessed September 13, 2017 (2011).
- 117.Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol. 2010;161:629–42. https://doi.org/10.1111/j.1476-5381.2010.00908.x.PubMedPubMedCentralCrossRefGoogle Scholar
- 120.Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab. 2017;19:1233–41. https://doi.org/10.1111/dom.12926.PubMedCrossRefGoogle Scholar
- 122.Serge Jabbour, T. R. P., Julio Rosenstock, Marie-Louise Hartoft-Nielson, Oluf Kristian Hojbjerg Hansen, and Melanie Davies. Abract OR15-3 Robust dose-dependent glucose lowering and body weight (BW) reductions with the novel oral formulation of semaglutide in patients with early type 2 diabetes (T2D). Endocrine Society 2016 https://endo.confex.com/endo/2016endo/webprogram/Paper25706.html (April 2, 2016).
- 126.Hansen MSS, Tencerova M, Frolich J, Kassem M, Frost M. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on bone cell metabolism. Basic Clin Pharmacol Toxicol. 2017;122:25–37. https://doi.org/10.1111/bcpt.12850.PubMedCrossRefGoogle Scholar
- 127.Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993;138:159–66.PubMedCrossRefGoogle Scholar
- 135.Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab. 2016;18:1176–90. https://doi.org/10.1111/dom.12735.PubMedPubMedCentralCrossRefGoogle Scholar
- 136.•• Farooqi IS, O'Rahilly S. 20 years of leptin: human disorders of leptin action. J Endocrinol. 2014;223:T63–70. https://doi.org/10.1530/joe-14-0480. The discovery of leptin has provided a robust framework to build our current understanding of energy regulation. This review describes how the identification of humans with mutations in leptin or leptin receptor has provided insight into leptin-responsive pathways controling eating behavior PubMedCrossRefGoogle Scholar